Different antitumor immunity roles of cytokine activated T lymphocytes from naïve murine splenocytes and from dendritic cells-based vaccine primed splenocytes: Implications for adoptive immunotherapy

Experimental Oncology

Volumn 26, Issue 1, 2004, Pages 55-62

  Zhang, Sheng ^a   Wang, Qin ^b   Li, Wen Feng ^a   Wang, Hong Yi ^a   Zhang, Hong Jun ^a   Zhu, Jing Juan ^a  

^a QINGDAO UNIVERSITY   (China)

^b ZIBO CENTRAL HOSPITAL   (China)

Author keywords

Cytotoxicity; Dendritic cells; Tumor immunity; Vaccination

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; MONOCLONAL ANTIBODY CD3; TUMOR VACCINE; CANCER VACCINE; CAT VACCINE; CHROMIUM 51; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; SET VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; EFFECTOR CELL; IMMUNOCOMPETENCE; IMMUNOLOGICAL MEMORY; LETHAL MUTANT; LEUKEMIA; LONG TERM MEMORY; MOUSE; NONHUMAN; PHENOTYPE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TARGET CELL; VACCINATION; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; IN VIVO STUDY; LYMPHATIC LEUKEMIA; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, EXPERIMENTAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; SPLEEN; T-LYMPHOCYTES;

EID: 1942473781     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
2. Fields RS, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune response in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482-7.
3. Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mule JJ. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001; 61: 8513.
4. Schmidt-Wolf I GH, Negrin RS, Kiem H-P, Blume KG, Weissman IL. Use of a SCID mouse /human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991; 174: 139-49.
5. Schmidt-Wolf I GH, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21: 1673-9.
6. You S, Maeda S, Murao S, Takahashi R, Ishikawa J, Miyazawa M, Nose M, Sugiyama T. Establishment and characterization of mouse leukemia cell lines L615K and L7212K derived from transplantable murine leukemias maintained in China. Jpn J Cancer Res 1989; 80: 444-51.
7. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate antitumor immune responses in vivo. Nat Med 1999; 5: 405-11.
8. Syrengelas AD, Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J Immunol 1999; 162: 4790-5.
9. Saxton M, Longo DL, Wetzel HE, Tribble H, Alvord WG, Kwak LW, Leonard AS, Ullmann CD, Curti BD, Ochoa AC. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood 1997; 89: 2529-36.
10. Gold JE, Zachary DT, Osband ME. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Int J Cancer 1995; 61: 580-6.
11. + natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production. Blood 2001; 97: 2923-31.
12. Makrigiannis AP, Musgrave BL, Hoskin DW. Differential effects of B7-1 and B7-2 on the costimulation of mouse nonspecific cytotoxic T lymphocyte development in response to anti-CD3 antibody. J Leukoc Biol 1999; 66: 792-802.
13. Yun YS, Hargrove ME, Ting C. Heterogeneity of long term cultured activated killer cells induced by anti-T3 antibody. J Immunol 1988; 141: 1390-7.
14. Yun Y-S, Hargrove ME, Ting C-C. In vivo antitumor activity of anti-CD3-induced activated killer cells. Cancer Res 1989; 49: 4770-4.
15. Loeffler CM, Platt JL, Anderson PM, Katsanis E, Ochoa JB, Urba WJ, Longo DL, Leonard AS, Ochoa AC. Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. Cancer Res 1991; 51: 2127-32.
16. Yoshizawa H, Chang A, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 147: 729-37.
17. Yoshizawa H, Chang A, Shu S. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin2-activated tumor-draining lymph node cells. Cancer Res 1992; 52: 1129-36.
18. Tanaka H, Yoshizawa H, Yamaguchi Y, Ito Kazuhisa, Kagamu H, Suzuki E, Gejyo F, Hamada H, Arakawa M. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells J Immunol 1999; 162: 3574-82.
19. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687.
20. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3+CD56+ cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency mice. Blood 1998; 92: 3318.
21. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J Immunol 1996; 156: 2918-26.
22. Schnurr M, Galambos P, Scholz C, Then F, Dauer M, Endres S, Eigler A. Tumor cell lysate-pulsed human dendritic cells induce a T cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res 2001; 61: 6445-50.
23. Porgador A, Gilboa EH. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182: 255-60.
24. Boczkowski D, Nair SK, Nam J, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60: 1028-34.
25. + T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol 2001; 167: 5678-88.
26. Pourbohloul SC, Thurlow SM, Furmanski P, Johnson CS. Induction of permanent regression of friend virus leukemia by adoptive transfer of T helper and not T cytotoxic cells. Leukemia Res 1992; 16: 881-7.
27. Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 1998; 101: 429-41.
28. hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95: 2024-30.
29. + tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647-58.
30. Nagoshi M, Goedegebuure PS, Burger UL, Sadanaga N, Chang MP, Eberlein TJ. Successful adoptive cellular immunotherapy is dependent on induction of a host immune response triggered by cytokine producing donor tumor-infiltrating lymphocytes. J Immunol 1998; 160: 334-44.
31. Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001; 167: 6497-502.
32. Greenberg PD, Cheever MA. Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells. J Immunol 1984; 133: 3401-7.